Overview

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Status:
Withdrawn
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying whether a new experimental cancer study drug BAY 1000394 will be helpful in treating solid tumor cancer with an abnormality in one of the following genes: Mcl-1, Myc or CCNE.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bayer